ClinicalTrials.gg
Not yet recruitingNCT07807592Updated Sep 8, 2026

Ultrasound-Guided Posterior Quadratus Lumborum Block With Bupivacaine and Dexmedetomidine Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery

A Phase 4 interventional study of Intrathecal Morphine and Ultrasound-Guided Posterior Quadratus Lumborum Block in Postoperative Analgesia After Cesarean Delivery, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Assiut University · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Cesarean delivery (CD) is one of the most commonly performed surgical procedures worldwide, with millions of women undergoing the procedure annually (1). Despite advances in surgical techniques and perioperative care, postoperative pain management remains a significant clinical challenge (2). Moderate to severe postoperative pain is commonly reported following CD, which can seriously impair daily activities, hinder maternal-infant bonding, delay recovery, and increase the risk of negative psychological outcomes, including postpartum depression and chronic pain syndromes. Effective postoperative analgesia is crucial not only for maternal comfort but also for optimizing recovery outcomes. Adequate pain control facilitates early mobilization, reduces hospital length of stay, promotes breastfeeding initiation, and strengthens the maternal-infant relationship Consequently, clinicians continuously refine postoperative analgesic protocols to enhance both effectiveness and safety while minimizing adverse effects that could compromise maternal and neonatal well-being. The Challenge of Post-Cesarean Analgesia Intrathecal morphine (ITM) has long been considered the "gold standard" for postoperative analgesia following cesarean delivery due to its excellent analgesic efficacy and prolonged duration of action (3). Administered as a single injection during spinal anesthesia, ITM provides effective pain relief for 12-24 hours postoperatively, making it a cornerstone of enhanced recovery after cesarean (ERAC) protocols. However, ITM is associated with a significant side-effect profile that limits its clinical utility. Higher doses, while offering superior pain control, substantially increase the risk of adverse effects including pruritus, postoperative nausea and vomiting (PONV), urinary retention, and potentially life-threatening respiratory depression. Studies have demonstrated that pruritus occurs in up to 91% of patients receiving 200 mcg of ITM, while respiratory depression risk increases significantly with doses exceeding 0.3 mg (6). Although dose reduction can mitigate these effects, the optimal dose that balances analgesia with an acceptable side-effect profile remains controversial. Some evidence suggests that doses as low as 0.025-0.075 mg may be sufficient when combined with multimodal analgesia (5,6). ltrasound-guided regional nerve blocks have emerged as valuable components of multimodal analgesia, offering the potential for effective pain relief while reducing systemic opioid exposure. Among these techniques, the quadratus lumborum block (QLB) has gained significant attention for abdominal surgeries, including cesarean delivery. The QLB targets the fascial planes surrounding the quadratus lumborum muscle. Unlike the transversus abdominis plane (TAP) block, which primarily provides somatic analgesia of the anterolateral abdominal wall, the QLB offers potential advantages including more extensive sensory blockade (T6-L3) and the ability to address both somatic and visceral pain components through spread of local anesthetic to the paravertebral space (4,7) between groups. Evidence suggests that bilateral QLB provides more effective postoperative pain relief than TAP blocks for cesarean delivery, with better visceral pain control and greater opioid-sparing effects. The addition of dexmedetomidine as an adjuvant to local anesthetics in QLB has shown promising results. Dexmedetomidine, a selective alpha-2 adrenergic agonist, possesses analgesic and sedative properties without respiratory depression. Studies have demonstrated that perineural dexmedetomidine prolongs the duration of local anesthetic action, likely through localized vasoconstriction and inhibition of nerve fiber action potentials. Clinical trials have found that adding dexmedetomidine to bupivacaine in QLB significantly prolongs the time to first rescue analgesia request Study Aims and Hypotheses Primary Aim: To compare the analgesic efficacy of ultrasound-guided bilateral QLB with bupivacaine and dexmedetomidine versus intrathecal morphine for postoperative analgesia following elective cesarean delivery.

02

Conditions studied

  • Postoperative Analgesia After Cesarean Delivery
03

In context

Lead sponsor

Assiut University is the lead sponsor of 5,092 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years • Singleton pregnancy • Term pregnancy (≥ 37 weeks gestation) • Scheduled for elective cesarean delivery under spinal anesthesia • (ASA) physical status II or III • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • to spinal anesthesia or regional nerve blockade • Known to any study medication (bupivacaine, dexmedetomidine, morphine) • Significant cardiovascular, pulmonary, hepatic, or renal disease • Preeclampsia or eclampsia • Coagulopathy or bleeding diathesis • Infection at the injection site • Chronic pain conditions • Current opioid use or substance abuse • History of psychiatric illness that may interfere with pain assessment • Emergency cesarean delivery
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group ITM

    Intrathecal morphine (100 μg) administered with spinal anesthesia

    Drug: Intrathecal Morphine

  • Active comparator
    Group QLB:

    Bilateral ultrasound-guided QLB with 0.25% bupivacaine (25 mL per side) plus (0.5 μg/kg) dexmedetomidine.

    Procedure: Ultrasound-Guided Posterior Quadratus Lumborum Block

Interventions

  • Intrathecal morphine (100 μg) administered with spinal anesthesia

  • ProcedureUltrasound-Guided Posterior Quadratus Lumborum Block

    QLB will be performed. Under ultrasound guidance (low-frequency curvilinear probe), the quadratus lumborum muscle will be identified posterior to the transversalis fascia. A 22-gauge 80-100 mm needle will be inserted using an in-plane approach, and 25 mL of 0.25% bupivacaine with dexmedetomidine 0.5 μg/kg will be injected on each side after negative aspiration. The block will be performed bilaterally

06

What researchers measure

Primary outcomes

  1. Cumulative intravenous morphine consumption

    Cumulative intravenous morphine consumption at 24 hours postoperatively

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 8, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07807592
Lead sponsor
Assiut University
Responsible party
Ahmed Omar Mohammed (Resident doctor at Anesthesia, Intensive Care and Pain Management, Assiut University) — Principal investigator
First posted
Sep 8, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Morphine

Start the discussion